David Shaw’s Blueprint Medicines BPMC Stock Holding History

David Shaw’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,600	Closed	-$846K	–	4577
2025 Q2	$846K	Hold	6,600	–	–	﹤0.01%	3345
2025 Q1	$584K	Hold	6,600	–	–	﹤0.01%	3412
2024 Q4	$576K	Sell	6,600 -7,300	-53%	-$669K	﹤0.01%	3527
2024 Q3	$1.29M	Buy	13,900 +3,300	+31%	+$328K	﹤0.01%	3081
2024 Q2	$1.14M	Buy	10,600 +3,300	+45%	+$330K	﹤0.01%	3098
2024 Q1	$692K	Hold	7,300	–	–	﹤0.01%	3316
2023 Q4	$673K	Hold	7,300	–	–	﹤0.01%	3380
2023 Q3	$367K	Buy	+7,300	New	+$390K	﹤0.01%	3538

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

David Shaw's BPMC Position: Q2 2025 in Review

David Shaw sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 388,986 shares — an estimated $40.4M sold.

David Shaw first reported a position in BPMC in Q2 2015 and held it in 28 quarters. The position peaked at $35.7M in Q1 2024. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

David Shaw reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
David Shaw sold 388,986 Blueprint Medicines shares in Q2 2025, an estimated $40.4M.
David Shaw first reported a position in Blueprint Medicines in Q2 2015 and held it in 28 quarters.
David Shaw's Blueprint Medicines position peaked at $35.7M in Q1 2024.
355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.